{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:32:43Z","timestamp":1781641963682,"version":"3.54.5"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Carbapenem antibiotics are critical therapies for multidrug-resistant infections, but their comparative haematologic safety profiles remain poorly characterized. We systematically evaluated haematologic adverse events associated with meropenem, ertapenem, imipenem and doripenem using pharmacovigilance data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed the FDA Adverse Event Reporting System (FAERS) database from January 2013 to July 2025. Disproportionality analysis was performed using reporting odds ratios (RORs) with 95% confidence intervals for haematologic adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen distinct haematologic adverse events were identified. Meropenem demonstrated the most extensive toxicity profile with significant signals for 15 adverse events, including severe conditions: thrombocytosis (ROR\u200a=\u200a24.941), eosinophilia (ROR\u200a=\u200a24.663), bone marrow failure (ROR\u200a=\u200a13.113), agranulocytosis (ROR\u200a=\u200a11.57) and pancytopenia (ROR\u200a=\u200a11.131). Imipenem demonstrated signals for nine events, notably thrombocytopenia and eosinophilia. Ertapenem demonstrated nine events: leucopenia (ROR\u200a=\u200a3.843) and neutropenia (ROR\u200a=\u200a2.469). No reports were identified for doripenem.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Significant differences exist in haematologic safety profiles among carbapenems. Meropenem shows the broadest spectrum of severe toxicity, while other carbapenems demonstrate fewer reports. demonstrates fewer reported haematologic safety signals and not a most favourable haematologic safety profile. These differential safety profiles should inform further studies on carbapenem selection, including patients with baseline haematologic disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag060","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T12:35:54Z","timestamp":1770467754000},"source":"Crossref","is-referenced-by-count":2,"title":["A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4080-3030","authenticated-orcid":false,"given":"Connor","family":"Frey","sequence":"first","affiliation":[{"name":"Department of Medicine, University of British Columbia , 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1036-6702","authenticated-orcid":false,"given":"Parham","family":"Elmi","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia , 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"2026022009494457300_dkag060-B1","doi-asserted-by":"publisher","first-page":"e00079","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae","volume":"31","author":"Rodr\u00edguez-Ba\u00f1o","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"2026022009494457300_dkag060-B2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026022009494457300_dkag060-B3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"2026022009494457300_dkag060-B4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/17512433.2025.2465427","article-title":"Optimizing meropenem therapy in critical infections: a review of pharmacokinetics\/pharmacodynamics research and clinical practice","volume":"18","author":"Liao","year":"2025","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"Suppl 2","key":"2026022009494457300_dkag060-B5","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.1093\/clinids\/24.Supplement_2.S266","article-title":"The pharmacology of meropenem, a new carbapenem antibiotic","volume":"24","author":"Craig","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2026022009494457300_dkag060-B6","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jac\/dkg404","article-title":"Ertapenem, the first of a new group of carbapenems","volume":"52","author":"Shah","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2026022009494457300_dkag060-B7","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2165\/00003495-200363170-00006","article-title":"Ertapenem","volume":"63","author":"Curran","year":"2003","journal-title":"Drugs"},{"key":"2026022009494457300_dkag060-B8","doi-asserted-by":"publisher","first-page":"106299","DOI":"10.1016\/j.jinf.2024.106299","article-title":"Outpatient parenteral antimicrobial therapy with carbapenems: a systematic review","volume":"89","author":"Wolie","year":"2024","journal-title":"J Infect"},{"key":"2026022009494457300_dkag060-B9","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3390\/microorganisms9071505","article-title":"Beta-lactams toxicity in the intensive care unit: an underestimated collateral damage?","volume":"9","author":"Roger","year":"2021","journal-title":"Microorganisms"},{"key":"2026022009494457300_dkag060-B10","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1093\/jac\/dku111","article-title":"The risk of seizures among the carbapenems: a meta-analysis","volume":"69","author":"Cannon","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026022009494457300_dkag060-B11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00003495-199651010-00008","article-title":"Imipenem\/cilastatin","volume":"51","author":"Balfour","year":"1996","journal-title":"Drugs"},{"key":"2026022009494457300_dkag060-B12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1086\/600036","article-title":"Doripenem","volume":"49","author":"Paterson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026022009494457300_dkag060-B13","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1128\/aac.02109-13","article-title":"Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia","volume":"58","author":"Luyt","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026022009494457300_dkag060-B14","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1093\/jac\/dkw200","article-title":"Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence","volume":"71","author":"Crandon","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026022009494457300_dkag060-B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04453-9","article-title":"Abnormal coagulation indicators associated with \u03b2-lactamantibacterial drug: a pharmacovigilance study based on the FAERS database","author":"Tian","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2026022009494457300_dkag060-B16","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1111\/trf.16295","article-title":"Immune thrombocytopenia induced by beta-lactam antibiotics: cross-reactions of responsible antibodies with other beta-lactam drugs","volume":"61","author":"Slaught","year":"2021","journal-title":"Transfusion"},{"key":"2026022009494457300_dkag060-B17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1001\/archinte.159.6.607","article-title":"Incidence of \u03b2-lactam\u2013induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis","volume":"159","author":"Olaison","year":"1999","journal-title":"Arch Intern Med"},{"key":"2026022009494457300_dkag060-B18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/antib13030059","article-title":"Adverse events of PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: an analysis of the FDA adverse events database","volume":"13","author":"Frey","year":"2024","journal-title":"Antibodies"},{"key":"2026022009494457300_dkag060-B19","doi-asserted-by":"publisher","first-page":"111328","DOI":"10.1016\/j.jocn.2025.111328","article-title":"Disproportionality analysis of progestogens and estrogens demonstrates increased meningioma risk","volume":"137","author":"Frey","year":"2025","journal-title":"J Clin Neurosci"},{"key":"2026022009494457300_dkag060-B20","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA \u2013 inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"2026022009494457300_dkag060-B21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/pharma3040026","article-title":"Cardiovascular adverse events associated with prostate cancer treatment: a disproportionality analysis from the food and drug administration adverse event reporting system database","volume":"3","author":"Frey","year":"2024","journal-title":"Pharmacoepidemiology"},{"issue":"Suppl A","key":"2026022009494457300_dkag060-B22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/jac\/36.suppl_A.207","article-title":"Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem","volume":"36","author":"Norrby","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"2026022009494457300_dkag060-B23","doi-asserted-by":"publisher","first-page":"e243443","DOI":"10.1136\/bcr-2021-243443","article-title":"Meropenem-induced thrombocytopenia: a paediatric case","volume":"14","author":"Cachia","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2026022009494457300_dkag060-B24","first-page":"156","article-title":"Meropenem induced severe thrombocytopenia in an adult patient: a case report","volume":"10","author":"Dawaiwala","year":"2021","journal-title":"J Krishna Inst Med Sci Univ"},{"key":"2026022009494457300_dkag060-B25","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1111\/trf.14267","article-title":"Meropenem-induced immune thrombocytopenia and the diagnostic process of laboratory testing","volume":"57","author":"Huang","year":"2017","journal-title":"Transfusion"},{"key":"2026022009494457300_dkag060-B26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13256-020-02632-1","article-title":"Meropenem-induced pancytopenia in a preterm neonate: a case report","volume":"15","author":"Hussain","year":"2021","journal-title":"J Med Case Reports"},{"key":"2026022009494457300_dkag060-B27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s15010-015-0784-8","article-title":"Ertapenem usage in cancer patients with and without neutropenia: a report on 97 cases from a comprehensive cancer center","volume":"43","author":"Nesher","year":"2015","journal-title":"Infection"},{"key":"2026022009494457300_dkag060-B28","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1128\/aac.02721-14","article-title":"Safety and efficacy of long-term outpatient ertapenem therapy","volume":"58","author":"Qureshi","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026022009494457300_dkag060-B29","doi-asserted-by":"publisher","first-page":"e1263","DOI":"10.7759\/cureus.1263","article-title":"Ertapenem-induced thrombocytosis","volume":"9","author":"Docobo","year":"2017","journal-title":"Cureus"},{"key":"2026022009494457300_dkag060-B30","doi-asserted-by":"publisher","first-page":"004283","DOI":"10.12890\/2024_004283","article-title":"Acute thrombocytosis in a patient treated with ertapenem","volume":"11","author":"Sarfo","year":"2024","journal-title":"Eur J Case Rep Intern Med"},{"key":"2026022009494457300_dkag060-B31","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3390\/microorganisms9071477","article-title":"Common and rare hematological manifestations and adverse drug events during treatment of active TB: a state of art","volume":"9","author":"Minardi","year":"2021","journal-title":"Microorganisms"},{"key":"2026022009494457300_dkag060-B32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.5414\/CP204215","article-title":"Imipenem cilastatin sodium-associated thrombocytopenia in an older patient: a case report and literature review","volume":"60","author":"Qiao","year":"2022","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2026022009494457300_dkag060-B33","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00277-019-03634-w","article-title":"Doripenem versus meropenem as first-line empiric therapy of febrile neutropenia in patients with acute leukemia: a prospective, randomized study","volume":"98","author":"Oyake","year":"2019","journal-title":"Ann Hematol"},{"issue":"Suppl 1","key":"2026022009494457300_dkag060-B34","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1086\/599813","article-title":"Safety of intravenous infusion of doripenem","volume":"49","author":"Redman","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026022009494457300_dkag060-B35","doi-asserted-by":"publisher","first-page":"004593","DOI":"10.12890\/2024_004593","article-title":"Neutropenia induced by ceftriaxone and meropenem","volume":"11","author":"Aung","year":"2024","journal-title":"Eur J Case Rep Intern Med"},{"key":"2026022009494457300_dkag060-B36","doi-asserted-by":"publisher","first-page":"001462","DOI":"10.1099\/jmm.0.001462","article-title":"JMM profile: carbapenems: a broad-spectrum antibiotic","volume":"70","author":"Armstrong","year":"2021","journal-title":"J Med Microbiol"},{"key":"2026022009494457300_dkag060-B37","doi-asserted-by":"publisher","first-page":"4029648","DOI":"10.1155\/2018\/4029648","article-title":"Antimicrobial-induced cytopenia and bone marrow hypocellularity in patients with cirrhosis","volume":"2018","author":"Patil","year":"2018","journal-title":"Bone Marrow Res"},{"key":"2026022009494457300_dkag060-B38","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.2169\/internalmedicine.54.3385","article-title":"Intravascular hemolytic anemia in a patient with antibodies related to meropenem","volume":"54","author":"Oka","year":"2015","journal-title":"Intern Med"},{"key":"2026022009494457300_dkag060-B39","doi-asserted-by":"publisher","first-page":"03000605231162434","DOI":"10.1177\/03000605231162434","article-title":"Cross-reactivity between piperacillin\u2013tazobactam and cefoperazone\u2013sulbactam in drug-induced immune thrombocytopenia","volume":"51","author":"He","year":"2023","journal-title":"J Int Med Res"},{"key":"2026022009494457300_dkag060-B40","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: a 2022 practice parameter update","volume":"150","author":"Khan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026022009494457300_dkag060-B41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11882-016-0594-9","article-title":"Cross-reactivity among beta-lactams","volume":"16","author":"Romano","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"2026022009494457300_dkag060-B42","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/cid\/ciu587","article-title":"A systematic review: can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins?","volume":"59","author":"Kula","year":"2014","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag060\/67020159\/dkag060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag060\/67020159\/dkag060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:49:47Z","timestamp":1771598987000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag060\/8493043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag060","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,2]]},"article-number":"dkag060"}}